Mark your calendars! Webinar “Next-gen vectors: advancing in vivo and ex vivo gene delivery through intelligent design” Sept 3, 2025

Webinar: Weds September 3, 2025
08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST

Title: Next-gen vectors: advancing in vivo and ex vivo gene delivery through intelligent design

As therapeutic developers push the demands of viral vectors to deliver a gene(s) of interest, with larger payloads, constitutive expression, safety switches and targeted delivery, expert guided vector design is critical.

This webinar will highlight two case studies:

Nagy Habib MD, ChM, FRCS, CEO, Dawn Therapeutics, will share the complex nature of the regulatory elements required of their vector, the process for iterative selection, and getting to a vector with a functional titre.

John Maher, MD, CSO, Leucid Bio, will present their story of selecting the proper vector delivery model, and the various options they tested to land on their final candidate.

Both vectors are now in the clinic, and we will hear updates on the progress from the clinical trials.

Carlo Scala, our Director of Process Development and Innovation, is a member of the team that has designed and developed 100+ vectors. He will discuss data-driven machine learning algorithms that can help select the proper promoters and regulatory elements to provide precision in gene expression.
 
Register today! https://lnkd.in/eyh9kYwQ

Get in touch. Nicholas Ostrout, Ph.D. Makis Sigalas, PhD Elaine Rihn

BioInsights #viralvectors #genetherapy #lentiviralvectors #cellandgenetherapy #celltherapy #biotechInnovation #viralvectordesign